 At the end of the 10-day study, the subject will be offered testing of their virus for resistance to approved drugs genotype and transferred to their physician for continued treatment with FDA-approved antiretroviral therapies. If the subject experiences a side effect, which continues past the end of the study, they will be further monitored until the side effect goes away. 